Plus   Neg

Bio-Path Rises On New Patent For Prexigebersen

Shares of Bio-Path Holdings Inc. (BPTH) are up more than 37% at $5.60 in pre-market trading Thursday on receipt of notice of allowance for a strategic patent for its lead product candidate Prexigebersen in combination with either a cytidine analog such as Decitabine or Bcr-Abl tyrosine kinase inhibitors like Dasatinib and Nilotinib in a variety of cancers.

Prexigebersen in combination with Decitabine is currently in a phase II clinical trial as a treatment for acute myeloid leukemia.

Commenting on the new patent, Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings, said, "Our growing patent estate continues to be a valuable asset for Bio-Path as it provides protection not only for our core product portfolio and research efforts but now also offers broad protection in combination with established front-line therapies."

BPTH closed Wednesday's trading at $4.11, up 1.48%. In pre-market trading Thursday, the stock is up 37.90% at $5.64.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration is hastening its efforts to make available more at-home testing options in response to the ongoing COVID-19 pandemic. All At-Home Covid-19 Tests being used now are authorized only for emergency use, and not cleared or fully approved by the FDA. The recent granting of EUA for the Quidel Corp.'s QuickVue At-Home COVID-19 Test is one example. Dollar Tree Inc. (DLTR) Wednesday reported a profit for the fourth-quarter that climbed 309 percent from last year, while Wendy's Co. (WEN) posted a profit that grew about 46.0 percent from the prior year. Dollar Tree has increased its share repurchase authorization by $2.0 billion. Wendy's expects profit for fiscal year 2021 to be below analysts' expectations. Medical devices company Boston Scientific Corp. (BSX) agreed Wednesday to acquire the global surgical business of Israel-based Lumenis LTD from an affiliate of Baring Private Equity Asia (BPEA) for an upfront cash payment of $1.07 billion, subject to closing adjustments. Lumenis is a privately-held...
Follow RTT